News

Mr Zhou was a partner and managing director of Eos Funds, where he directed investments in Chinese companies which intended to list on US and Canadian exchanges. Mr

In addition, Mr Renz will play a key role in developing strategic partnerships and alliances. He will report directly to Branislav Vajdic, who continues as the company’s CEO.

The license is for tests related to the detection, monitoring and risk assessment of pre-eclampsia, a leading cause of maternal death. In addition, Beckman Coulter obtained rights to

Led by Eleftherios Diamandis, the project team in Toronto will use Thermo Fisher Scientific’s mass spectrometers, in collaboration with the Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center

The new company will retain the name Noteworthy Medical Systems and will serve a combined customer base of more than 1,200 practices, 5,700 healthcare providers and 12,000 users

The program is composed of two separate Phase III clinical trials involving a total of 540 patients and being carried out in parallel in a total of 14

Under the terms of the agreement, Milestone will pay Access upfront license fees and subsequent milestone payments that total $10 million along with a double digit royalty upon

Terms of the sale include an upfront payment of $1 million in cash paid at closing to Forbes along with potential future payments of up to $6 million,

Paul Reid, CEO of ReceptoPharm, said: “Initial reports and feedback from physicians involved with this clinical study have reported that patients have experienced no adverse side effects from